The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 February 2026•

1 min read

Gilead Sciences Posts Strong Q4, Shares Fall on Weak Guidance; Analysts Remain Bullish

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Gilead Sciences reported robust fourth-quarter earnings, surpassing consensus estimates for both EPS and revenue. This strong performance was primarily driven by its HIV prevention therapies and the successful launch of Yeztugo. However, the company's shares experienced a decline in pre-market trading after it issued weaker-than-expected fiscal 2026 guidance. Despite this cautious outlook, several prominent analysts, including Needham, Scotiabank, and Cantor Fitzgerald, reaffirmed their positive ratings. These firms also raised their price targets for Gilead, highlighting a divergence between the company's near-term performance and its future projections. The market reaction reflects a mixed sentiment, weighing strong current results against future uncertainties.